Illumina’s DNA sequencing cancer tests to check 500 genes get US nod
The US Federal Drug Administration approved Illumina Inc.’s DNA sequencing cancer tests that check more than 500 genes in a tumour to help.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US Federal Drug Administration approved Illumina Inc.’s DNA sequencing cancer tests that check more than 500 genes in a tumour to help.
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.
BioNTech, a German immunotherapy company, announced a strategic pact with OncoC4, a private firm, to develop and commercialise a drug to treat solid tumours.
Pfizer will acquire Seagen for $43 billion to beef up its cancer portfolio, with COVID-19 vaccine sales forecast to plummet.